CoChat

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

Open access
Lonial, Sagar, Richardson, Paul G, San Miguel, Jesús, Sonneveld, Pieter, Schuster, Michael W, Bladé, Joan, Cavenagh, Jamie, Rajkumar, S. Vincent, Jakubowiak, Andrzej J, Esseltine, Dixie‐Lee, Anderson, Kenneth C, Harousseau, Jean‐Luc · 2008 · British Journal of Haematology
Cited by 94

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Summary: Haematological toxicities and thromboembolic (TE) events are common complications of myeloma therapy. TE risk may be elevated with combination regimens, notably thalidomide/lenalidomide plus high‐dose dexamethasone; concomitant erythropoietin appears to further increase the risk with lenalidomide–dexamethasone. We characterised thrombocytopenia and neutropenia in the phase 3 APEX (Assessment of Proteasome Inhibition for Extending Remissions) study of bortezomib versus high‐dose dexamethasone in relapsed myeloma, and calculated the incidences of deep‐vein thrombosis (DVT)/pulmonary embolism (PE) with: bortezomib or dexamethasone ± erythropoietin in APEX; bortezomib ± dexamethasone ± erythropoietin in two phase 2 studies of relapsed/refractory myeloma. Bortezomib‐associated thrombocytopenia and neutropenia were transient, predictable and manageable; mean platelet and neutrophil counts followed a cyclical pattern, and improved over the treatment course. Grade 3/4 thrombocytopenia incidence was higher with bortezomib versus dexamethasone (26%/4% vs. 5%/1%), but significant bleeding events were comparable (4% vs. 5%). DVT/PE incidence was low (≤3·1%) in all analyses; addition of dexamethasone/erythropoietin did not affect TE risk. In APEX, TE risk appeared lower with bortezomib versus dexamethasone. Bortezomib caused transient and cyclical thrombocytopenia and was not associated with elevated TE risk, alone or with dexamethasone ± erythropoietin. Preliminary data suggest bortezomib may reduce the thrombogenic potential of combination regimens via inhibition of platelet function or other mechanism‐specific effects on coagulation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2141.2008.07321.x

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 94

Metadata

Authors
Lonial, S., Richardson, P. G., San Miguel, J., Sonneveld, P., Schuster, M. W., Bladé, J., Cavenagh, J., Rajkumar, S. V., Jakubowiak, A. J., Esseltine, D., Anderson, K. C., & Harousseau, J.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2008-09-24
Volume
143
Issue
2
Pages
222-229
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2165065963
Cited by
94
References
5
FWCI
8.01
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. https://app.cochat.ai/papers/10.1111/j.1365-2141.2008.07321.x
The paper
Lonial, S., Richardson, P. G., San Miguel, J., Sonneveld, P., Schuster, M. W., Bladé, J., Cavenagh, J., Rajkumar, S. V., Jakubowiak, A. J., Esseltine, D., Anderson, K. C., & Harousseau, J. (2008). Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2008.07321.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.